610 related articles for article (PubMed ID: 26123862)
21. Common single nucleotide polymorphisms in transient receptor potential melastatin type 6 increase the risk for proton pump inhibitor-induced hypomagnesemia: a case-control study.
Hess MW; de Baaij JH; Broekman MM; Bisseling TM; Haarhuis BJ; Tan AC; Te Morsche RH; Hoenderop JG; Bindels RJ; Drenth JP
Pharmacogenet Genomics; 2017 Mar; 27(3):83-88. PubMed ID: 27926584
[TBL] [Abstract][Full Text] [Related]
22. Proton pump inhibitors linked to hypomagnesemia: a systematic review and meta-analysis of observational studies.
Cheungpasitporn W; Thongprayoon C; Kittanamongkolchai W; Srivali N; Edmonds PJ; Ungprasert P; O'Corragain OA; Korpaisarn S; Erickson SB
Ren Fail; 2015 Aug; 37(7):1237-41. PubMed ID: 26108134
[TBL] [Abstract][Full Text] [Related]
23. Prevalence and risk factors of long-term proton pump inhibitors-associated hypomagnesemia: a cross-sectional study in hospitalized patients.
Recart DA; Ferraris A; Petriglieri CI; Alonso Serena M; Bonella MB; Posadas-Martinez ML
Intern Emerg Med; 2021 Apr; 16(3):711-717. PubMed ID: 33001349
[TBL] [Abstract][Full Text] [Related]
24. Neonatal Histamine-2 Receptor Antagonist and Proton Pump Inhibitor Treatment at United States Children's Hospitals.
Slaughter JL; Stenger MR; Reagan PB; Jadcherla SR
J Pediatr; 2016 Jul; 174():63-70.e3. PubMed ID: 27131401
[TBL] [Abstract][Full Text] [Related]
25. Prevalence and outcomes of proton pump inhibitor associated hypomagnesemia in chronic kidney disease.
Hughes J; Y Y Chiu D; Kalra PA; Green D
PLoS One; 2018; 13(5):e0197400. PubMed ID: 29799851
[TBL] [Abstract][Full Text] [Related]
26. Characteristics of children and adolescents first prescribed proton pump inhibitors or histamine-2-receptor antagonists: an observational cohort study.
Ruigómez A; Kool-Houweling LMA; García Rodríguez LA; Penning-van Beest FJA; Herings RMC
Curr Med Res Opin; 2017 Dec; 33(12):2251-2259. PubMed ID: 28562108
[TBL] [Abstract][Full Text] [Related]
27. Proton pump inhibitors and hospitalization with hypomagnesemia: a population-based case-control study.
Zipursky J; Macdonald EM; Hollands S; Gomes T; Mamdani MM; Paterson JM; Lathia N; Juurlink DN
PLoS Med; 2014 Sep; 11(9):e1001736. PubMed ID: 25268962
[TBL] [Abstract][Full Text] [Related]
28. Proton-pump inhibitors do not influence serum magnesium levels in renal transplant recipients.
Van Ende C; Van Laecke S; Marechal C; Verbeke F; Kanaan N; Goffin E; Vanholder R; Jadoul M
J Nephrol; 2014 Dec; 27(6):707-11. PubMed ID: 24816563
[TBL] [Abstract][Full Text] [Related]
29. A case series of proton pump inhibitor-induced hypomagnesemia.
Hoorn EJ; van der Hoek J; de Man RA; Kuipers EJ; Bolwerk C; Zietse R
Am J Kidney Dis; 2010 Jul; 56(1):112-6. PubMed ID: 20189276
[TBL] [Abstract][Full Text] [Related]
30. Hypomagnesemia and proton-pump inhibitors.
Famularo G; Gasbarrone L; Minisola G
Expert Opin Drug Saf; 2013 Sep; 12(5):709-16. PubMed ID: 23808631
[TBL] [Abstract][Full Text] [Related]
31. Serum magnesium and proton-pump inhibitors use: a cross-sectional study.
Faulhaber GA; Ascoli BM; Lubini A; Mossmann M; Rossi G; Geib G; Furlanetto TW
Rev Assoc Med Bras (1992); 2013; 59(3):276-9. PubMed ID: 23680271
[TBL] [Abstract][Full Text] [Related]
32. Choice of Acid Suppressant Therapy and Long-Term Graft Outcomes After Kidney Transplantation.
January SE; Progar K; Nesselhauf NM; Hagopian JC; Malone AF
Pharmacotherapy; 2020 Nov; 40(11):1082-1088. PubMed ID: 33037663
[TBL] [Abstract][Full Text] [Related]
33. Maintenance therapy with proton pump inhibitors and risk of gastric cancer: a nationwide population-based cohort study in Sweden.
Brusselaers N; Wahlin K; Engstrand L; Lagergren J
BMJ Open; 2017 Oct; 7(10):e017739. PubMed ID: 29084798
[TBL] [Abstract][Full Text] [Related]
34. Comparative risk of incidence and clinical outcomes of COVID-19 among proton pump inhibitor and histamine-2 receptor antagonist short-term users: a nationwide retrospective cohort study.
Park J; You SC; Cho J; Park CH; Shin WG; Park RW; In Seo S
BMC Pharmacol Toxicol; 2022 Jan; 23(1):9. PubMed ID: 35039078
[TBL] [Abstract][Full Text] [Related]
35. Impact of long-term gastric acid suppression on spontaneous bacterial peritonitis in patients with advanced decompensated liver cirrhosis.
Huang KW; Kuan YC; Luo JC; Lin CL; Liang JA; Kao CH
Eur J Intern Med; 2016 Jul; 32():91-5. PubMed ID: 27139916
[TBL] [Abstract][Full Text] [Related]
36. Proton Pump Inhibitor Use, Hypomagnesemia and Risk of Cardiovascular Diseases: The Atherosclerosis Risk in Communities (ARIC) Study.
Rooney MR; Bell EJ; Alonso A; Pankow JS; Demmer RT; Rudser KD; Chen LY; Lutsey PL
J Clin Gastroenterol; 2021 Sep; 55(8):677-683. PubMed ID: 33471493
[TBL] [Abstract][Full Text] [Related]
37. Associations of Acid Suppressive Therapy With Cardiac Mortality in Heart Failure Patients.
Yoshihisa A; Takiguchi M; Kanno Y; Sato A; Yokokawa T; Miura S; Abe S; Misaka T; Sato T; Suzuki S; Oikawa M; Kobayashi A; Yamaki T; Kunii H; Nakazato K; Suzuki H; Saitoh SI; Takeishi Y
J Am Heart Assoc; 2017 May; 6(5):. PubMed ID: 28512114
[TBL] [Abstract][Full Text] [Related]
38. Treatment of hypomagnesemia.
Ayuk J; Gittoes NJ
Am J Kidney Dis; 2014 Apr; 63(4):691-5. PubMed ID: 24100128
[TBL] [Abstract][Full Text] [Related]
39. Histamine-2 receptor antagonists vs proton pump inhibitors on gastrointestinal tract hemorrhage and infectious complications in the intensive care unit.
MacLaren R; Reynolds PM; Allen RR
JAMA Intern Med; 2014 Apr; 174(4):564-74. PubMed ID: 24535015
[TBL] [Abstract][Full Text] [Related]
40. Prevalence of Prehypertension in Mexico and Its Association With Hypomagnesemia.
Rodríguez-Ramírez M; Simental-Mendía LE; González-Ortiz M; Martínez-Abundis E; Madero A; Brito-Zurita O; Pérez-Fuentes R; Revilla-Monsalve C; Islas-Andrade S; Rodríguez-Morán M; Guerrero-Romero F
Am J Hypertens; 2015 Aug; 28(8):1024-30. PubMed ID: 25618517
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
